ADAM17 Is The Main Sheddase For The Generation Of Human Triggering Receptor Expressed In Myeloid Cells (hTREM2) Ectodomain And Cleaves TREM2 After Histidine 157
D. Feuerbach, P. Schindler, C. Barske, S. Joller, E. Beng-Louka, K. A. Worringer, S. Kommineni, A. Kaykas, D. J. Ho, C. Ye, K. Welzenbach, G. Elain, L. Klein, I. Brzak, A. K. Mir, C. J. Faraday, R. Aichholz, S. Popp, N. George, C. L. Hsieh, M. C. Nakamura, U. Neumann
Abstract
Triggering receptor expressed in myeloid cells (TREM2) is a member of the immunoglobulin superfamily and is expressed in macrophages, dendritic cells, microglia, and osteoclasts. TREM2 plays a role in phagocytosis, regulates release of cytokine, contributes to microglia maintenance, and its ectodomain is shed from the cell surface. Using both pharmacological and genetic approaches we report here that the main protease contributing to the release of TREM2 ectodomain is ADAM17, (a disintegrin and metalloproteinase domain containing protein, also called TACE, TNF converting enzyme) while ADAM10 plays a minor role. Using mutational analysis, we demonstrate that the main cleavage site of the sheddases is located within the stalk region of TREM2 proximal to the plasma membrane. Complementary biochemical experiments reveal that cleavage occurs between histidine 157 and serine 158. Shedding is not altered for the R47H-mutated TREM2 protein that confers an increased risk for the development of Alzheimers disease. O-glycosylation is detected within the stalk region, but distant to the cleavage site. These findings reveal a link between shedding of TREM2 and its regulation during inflammatory conditions or chronic neurodegenerative disease like AD in which activity or expression of sheddases might be altered.
02 /Specification & Classification
Click any tag to browse matching papersReproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- The late onset Alzheimer's disease risk factor iRhom2/RHBDF2 is a modifier of microglial TREM2 proteolysis
Georg Jocher, Stephan A. Müller, … Stefan F. Lichtenthaler·Life Science AlliancePeer-reviewed·Mar 13, 2025
- FRMD8 promotes inflammatory and growth factor signalling by stabilising the iRhom/ADAM17 sheddase complex
U. Künzel, A. G. Grieve, … M. Freeman·bioRxiv·Jan 30, 2018
- As48, a First-in-Class Dual-Function TREM2 Modulator: Receptor Activation and Shedding Inhibition
Sungwoo Cho, Farida El Gaamouch, … Moustafa Tarek Gabr·Biomedicine & PharmacotherapyPeer-reviewed·Dec 1, 2025
- Sustained TREM2 stabilization accelerates microglia heterogeneity and Abeta pathology in a mouse model of Alzheimer s disease
Rahul Dhandapani, Marilisa Neri, … Ivan Galimberti·Cell ReportsPeer-reviewed·May 1, 2022
- TREM2-H157Y Increases Soluble TREM2 Production and Reduces Amyloid Pathology
Wenhui Qiao, Yixing Chen, … Guojun Bu·Molecular NeurodegenerationPeer-reviewed·Jan 31, 2023
- Intramembrane cleavage of TREM2 is determined by its intrinsic structural dynamics
Andrea Steiner, Kai Schlepckow, … Franz Hagn·The EMBO JournalPeer-reviewed·Aug 24, 2020